Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Expect Nothing Less Than Inexplicable Price Action @ CSE/OTC

<< Previous

Bullboard Posts

Next >>

Comment by C10H12N2on Jan 31, 2022 6:11pm

142 Views

Post# 34381835

RE:RE:RE:RE:Expect Nothing Less Than Inexplicable Price Action @ CSE/OTC

Directors going to work for others like Kal Malhi (blaring conflict of interest) has been tightened up significantly versus the conflict of interest clause at CSE. The Code of Ethics now written will meet Nasdaq standards. There is a difference. As to your Boogeyman complaint. It's like a soap opera that no one else is tuning into. The floor is all yours.

<< Previous

Bullboard Posts

Next >>

Gold vs. bitcoin, where should you invest?